View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 17, 2021updated 12 Jul 2022 11:06am

Informa Pharma introduces AI platform to enhance trial timelines

The AI platform’s machine learning engine facilitates enrolment forecasts at the site, country and overall trial level.

Informa Pharma Intelligence has introduced an artificial intelligence (AI)-based platform called Citeline Study Feasibility to expedite clinical trial decisions and timelines.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Designed to provide predictive analytics, the platform integrates its data sets with machine learning capabilities.

Trial feasibility and analytics teams can leverage the platform to simulate feasibility situations and boost enrolment potential for success over the long term, the company noted.

Referring to a recent study, Informa Pharma said about 85% of trials do not retain patients required to conduct a successful study and more than 90% of trials fail to meet their fixed completion deadlines.

Citeline Study Feasibility can address these challenges by delivering predictive insights optimised for trial site allocation and scoring. These insights also estimate enrolment duration and the overall possibility of enrolment success.

The machine learning engine of the platform enables enrolment forecasts at the site, country and overall trial level.

Based on these predictions, users can plan trial participation and fast-track the first patient enrolment.

The visual analyses of these scenarios generated by the platform allow understanding of trial design elements that positively or negatively impact enrolment timelines.

Users can optimise, compare and share the feasibility scenarios.

Informa Pharma Intelligence chief product and technology officer Nicky Marlin said: “The recent high-profile Covid-19 clinical trials demonstrated truly how important accelerated trial timelines can be to drug development.

“But too often, potentially lifesaving therapies encounter detrimental roadblocks in the form of incompatible sites and low clinical trial enrolment.

“Citeline Study Feasibility is uniquely positioned to take the manual effort out of the clinical trial planning process and give the industry the tools it needs to lower costs and make informed decisions for each study.”

In September last year, Australian company Opyl developed new software that can forecast the outcomes of Covid-19 clinical trials using artificial intelligence (AI).

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena